Stillbirth and repeat miscarriages carry heart attack risk Thelin (sitaxsentan): PAH drug withdrawn worldwidePfizer Canada is voluntarily withdrawing Thelin from the market worldwide due to concerns about hepatotoxicity. Lowering urate cuts cardiovascular deaths Hyperuricemia deserves more aggressive treatment, researcher says Teens: Cut the salt for future health Model predicts 3 g decrease in daily intake prevents thousands of cardiovascular events Huge trial backs cardiac resynchronization therapy Combined ICD-CRT device cuts mortality and heart failure hospitalizations Wireless feedback aids BP control Patient involvement is key to the success of telemonitoring, say Canadian researchers Rivaroxaban takes off as alternative to warfarin ROCKET AF trial suggests drug offers more user-friendly anticoagulation in atrial fibrillation Rosiglitazone: new Canadian restrictions Health Canada has issued new usage restrictions for rosiglitazone-containing products. Concomitant PPIs and antiplatelet agents OK Pharmacy BP screening lowers hospitalizations Ontario’s Cardiovascular Health Awareness Program targeted community-dwelling seniors First Previous 70 71 72 73 74 Next Last
